© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lung Cancer
CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC
June 26, 2020
Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.
Bemcentinib Induces Promising Activity With Pembrolizumab in cAXL-Positive NSCLC
June 25, 2020
"This interim clinical and translational data add further confidence to the potential patient benefit of selective AXL inhibition with bemcentinib, to reverse resistance to immune checkpoint inhibitors in selected cAXL-positive patients who have relapsed on immunotherapy."
Annamycin Demonstrates Efficacy for Lung Metastases in Preclinical Data
June 25, 2020
"In the case of sarcomas treated with the current standard of care, doxorubicin, tumors may be initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death."
Immunotherapy Combinations Provide Long-Term Benefit in Stage IV NSCLC
June 17, 2020
In an interview with Targeted Oncology, Suresh Ramalingam, MD, FASCO, discussed the findings from the CheckMate 227 study that support the FDA’s approval of the combination of nivolumab and ipilimumab in patients with advanced NSCLC.
FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC
June 15, 2020
"We are pleased to bring a new treatment choice to relapsed SCLC patients."
Individualizing Immunotherapy in Non–Small Cell Lung Cancer
June 15, 2020
Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.
Adherence to NCCN Guidelines for Biomarker Testing Shows Decreased Risk of Mortality for Non-Squamous aNSCLC
June 12, 2020
The NCCN guidelines recommend biomarker testing as a part of the pathologic evaluation for patients with non-squamous advanced NSCLC and NCC set out to determine how these guidelines decrease the incidence of mortality.
Four-Drug Atezolizumab Regimen Impacts Outcomes in Bulky NSCLC
June 08, 2020
In an interview with Targeted Oncology, Robert M. Jotte, MD, PhD, discussed the results of the exploratory analysis of patients with NSCLC from the IMpower150 who had bulky disease.
RET Inhibition Shows Significant Intracranial Responses in RET-Altered NSCLC
June 05, 2020
"Selpercatinib had marked intracranial anti-tumor activity in RET fusion–positive patients with [NSCLC and] CNS metastases. Tumor responses were durable, independently confirmed, and observed in patients with prior systemic chemotherapy."
Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review
June 01, 2020
"The ARROW trial results presented today during the ASCO virtual meeting showed that patients with RET fusion–positive lung cancer treated with the selective RET inhibitor pralsetinib had durable responses. In addition to supporting the development of pralsetinib across a broad population, these data highlight the urgency to test [patients with] lung cancer with next-generation sequencing so that eligible patients may be identified for treatment."